Airfinity is a disease forecasting company. It tracks, predicts and simulates population level disease outcomes in real time to inform decisions that can increase the global life span.

Multiple industries rely on global structured time series data sets and advanced forecasting​, from weather, to transport, to financial markets. The life science industry is far behind and based on siloed, national and static disease data – often based on self-reporting.

However, the life science industry is undergoing a data transformation driven by more and better personal health data, lower cost of diagnostics, better global data coverage and a range of other factors. Our approach is to ingest and structure any data point that has signal value and integrate it into our disease models in as close to real time as possible.
Airfinity provides scenario planning tools and forecasts that can be understood, relied upon and used for decision making across the life science ecosystem. We use a unique quant analytics approach, combining advanced meta science, statistics, epidemiology and machine learning solutions to dynamically understand true disease prevalence and underlying outcome drivers.

Airfinity has become the world’s leading source of disease forecasting, specialising in infectious diseases, cardiovascular, metabolic, and renal diseases and other critical areas including RNA. For example, ask us about the potential impact of a vaccine or treatment on hospitalisations, the impact of a new variant or strain on candidate effectiveness, or what different uptake scenarios will mean for the burden of disease.

Airfinity aims for the highest standards and quality, and at the same time operates at speed – clients get answers in hours, not months, so that we can be relied upon by the decision makers who know that the cost of failure is the cost of lives.